ProKidney Corp. (PROK) Research

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Market snapshot

Symbol
PROK
Price
$1.83
Day change
+4.57%
Market cap
$615.3M
P/E ratio
-3.47x
52-week range
0.54-7.13
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$4.67

Peer companies

  • Bicara Therapeutics Inc. Common Stock (BCAX)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Kura Oncology, Inc. (KURA)
  • Nanobiotix S.A. (NBTX)
  • Prime Medicine, Inc. (PRME)
  • Rezolute, Inc. (RZLT)
  • Septerna, Inc. (SEPN)
  • Savara Inc. (SVRA)

Recent insider activity

  • Girolamo Todd C — C-Conversion (163857 shares) on 2026-06-12
  • Girolamo Todd C — C-Conversion (163857 shares) on 2026-06-12
  • Girolamo Todd C — C-Conversion (163857 shares) on 2026-06-12
  • Locke Kenneth Thomas — trade (0 shares) on 2026-06-01
  • Lotvin Alan — A-Award (135000 shares) on 2026-05-28

Open ProKidney Corp. (PROK) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.